Amy Sun

Northwestern University — United States

Medicine · Health Sciences

16h-index1.2kcitations44works27.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), Immunotherapy and Immune Responses(8), Lymphoma Diagnosis and Treatment(6), Immune Cell Function and Interaction(6), Cutaneous lymphoproliferative disorders research(5)

Publications44 total

2510P Digital pathology prediction of luminal subtype and hormonal therapy responsiveness of prostate cancer patients
Annals of Oncology·2025
ABCL-942: Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-942 Pola-R-Mini-CHP for Untreated Diffuse Large B-Cell Lymphoma in Patients Who Are Elderly With Comorbid Conditions
Clinical Lymphoma Myeloma & Leukemia·2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Journal of Hepatology·2025· 5 citedOpen Access
Tinengotinib for Adult Patients with Advanced or Metastatic Cholangiocarcinoma: A Multicenter, Open-Label Phase 2 Trial
SSRN Electronic Journal·2025Open Access
A-226 Clonal evolution, antigens, and triggers in Cutaneous T Cell Lymphoma pathogenesis
European Journal of Cancer·2024
426 Immune reactions in dystrophic epidermolysis bullosa patients following gene therapy
Journal of Investigative Dermatology·2024Open Access
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
The Lancet·2024· 215 citedOpen Access
Differences in oncofertility beliefs, knowledge, and practice between medical oncologists and advanced practice providers: Identifying quality improvement targets.
Journal of Clinical Oncology·2023
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
Journal of Clinical Oncology·2023· 1 cited
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
Nature Medicine·2023· 172 citedOpen Access
Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors
Nature·2022· 2 citedOpen Access
Potentiating adoptive cell therapy using synthetic IL-9 receptors
Nature·2022· 109 citedOpen Access
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Journal for ImmunoTherapy of Cancer·2021· 8 citedOpen Access
Physiological expression and function of the MDR1 transporter in cytotoxic T lymphocytes
The Journal of Experimental Medicine·2020· 44 citedOpen Access
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids
Immunity·2020· 8 citedOpen Access
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis
Pharmacology·2020· 56 citedOpen Access
Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome
Journal of Investigative Dermatology·2019· 8 citedOpen Access
Transcriptomic Signatures in Airway Brushings and Lung Cancer Prognosis
2019
Distinct Requirements of CHD4 during B Cell Development and Antibody Response
Cell Reports·2019· 18 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Sergei B. Koralov(14), Mark S. Sundrud(8), Laura K. Fogli(5), Swati Goel(5), Maryaline Coffre(5), Niels Ødum(5), Jane P. F. Bai(4), Elliot Norry(4), Wei Cao(4), Mei Lan Chen(4), Sang Yong Kim(4), Kenneth B. Hymes(4), Gary Herman(4), Dejka M. Araujo(3), Mihaela Druta(3), Cheryl McAlpine(3), Dennis Williams(3), Hisako Kayama(3), Amber L. Delmas(3), Erumbi S. Rangarajan(3)